Microfluidic Formulation of DNA-Loaded Multicomponent Lipid Nanoparticles for Gene Delivery

With recent successes reflected in literature on mRNA delivery using LNPs, scientists from the University of Rome set out to investigate whether that success can be achieved with plasmid DNA delivery using LNPs (pDNA-LNPs). Authors Quagliarini et al. 2021 synthesized pDNA-LNPs using the NanoAssemblr’s tunable microfluidic technology and the impact of characteristics such as size and composition, and process parameters such as total flow rate (TFR) on in vitro transfection efficiencies were assessed. As a result, the paper illustrates small-sized homogenous pDNA-LNPs are capable of a higher transfection efficiency with lower cytotoxicity in three cell lines when compared to the conventional transfection agent Lipofectamine™ 3000. In vitro validation of the pDNA-LNPs in the study showcases precise control over composition through manipulation of TFRs and addition of PEGylation built into the bottom-up approach of NanoAssemblr® technology. Given this article’s assessment of pDNA-LNP physiochemical characteristics, further research can be conducted to accelerate the development of DNA-based vaccines, cancer immunotherapies, and gene therapies.

Microfluidic Formulation of DNA-Loaded Multicomponent Lipid Nanoparticles for Gene Delivery

Advanced Search

Browse by Category

related content

Lipid-based Nanoparticle Formulations for Small Molecules and RNA Drugs

Lipid Nanoparticle Delivery of siRNA to Osteocytes Leads to Effective Silencing of SOST and Inhibition of Sclerostin In Vivo.